FDA Publishes Guidance on Therapeutic Protein Biosimilars
The guidance discusses the design and evaluation of comparative analytical studies used to support the biosimilarity of a proposed therapeutic protein product to a reference product licensed under section 351(a) of the Public Health Service Act.
On May 21, 2019, FDA published guidance on the design and evaluation of comparative analytical studies used to support the biosimilarity of a proposed therapeutic protein product to a reference product licensed under section 351(a) of the Public Health Service Act (PHS Act). The guidance also offers recommendations on the scientific and technical information for the chemistry, manufacturing, and controls (CMC) portion of a marketing application for a proposed product submitted under section 351(k) of the PHS Act.
Among an overview of the PHS Act and the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), the guidance specifically discusses expression systems, manufacturing processes, physicochemical properties, functional activities, target binding, impurities, reference products and standards, finished drug products, and stability. Considerations addressed for a comparative analytical assessment include reference and biosimilar products and data analysis.
The guidance is part of a series of documents to facilitate the implementation of the BPCI Act. Other guidance documents address scientific considerations, biosimilar development, clinical pharmacology data, labeling of biosimilars, and demonstrating interchangeability.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
